Wegovy

For weight management, Wegovy (semaglutide 2.4 mg weekly) is the licensed option and generally achieves greater weight loss than the...

Choosing between Wegovy and Mounjaro comes down to what you’re aiming for (weight, blood sugar, side-effect profile) and what’s available to you. Many people see strong results with both; tirzepatide can yield greater reductions for some, while semaglutide has a longer real-world track record. Why these two drugs stand out Wegovy and Mounjaro are often compared because they’re part of the same family of treatments known as incretin-based medicines. Both act on hormones that h

Wegovy contains semaglutide, a GLP-1 receptor agonist used at higher weekly doses for weight management. It helps reduce appetite and supports lower energy intake alongside everyday habits like balanced eating and movement. What semaglutide actually is Semaglutide is a medicine that mimics GLP-1 (glucagon-like peptide-1), a natural hormone in the body. GLP-1 plays a key role in appetite and metabolism: it slows the emptying of the stomach, enhances the release of insulin when

Wegovy and Ozempic share the same active ingredient (semaglutide), but they’re licensed for different uses and doses — Wegovy for weight...

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both effective; some studies show larger average weight loss with tirzepatide, but individual response, side-effects, access, and clinical goals matter. The “better” choice is the one that fits your health needs and tolerability after a clinician review. Two medicines, two mechanisms Wegovy and Mounjaro both belong to a family of medicines that mimic natural gut hormones involved in appetite and metabolism. Wegovy contains s

Many people report fewer intrusive food thoughts, less urgency around snacking, and improved control in situations that previously triggered overeating. That can ease emotional or stress-linked eating because the immediate pull of ultra-palatable foods is quieter. Wegovy isn’t a treatment for mental-health conditions, so ongoing support — sleep, stress tools, counselling if needed — remains important. If mood changes occur, tell your clinical team so they can review and suppo

Storage is straightforward: keep pens in the refrigerator in their original carton, and do not freeze. Protect from light and check the...

Wegovy acts directly on GLP-1 receptors; effects on ghrelin and leptin are indirect and vary between individuals. By strengthening...

Wegovy is a once-weekly subcutaneous injection given into the abdomen, thigh, or upper arm. Rotate sites each week and avoid areas that...

There isn’t a one-off loading dose; instead there’s a gradual dose-escalation (titration) phase. You start low and step up in stages...

After stopping, many people regain some weight over time because appetite signals gradually return toward baseline. How much and how quickly varies, but the pattern is common across all weight-management approaches. Planning ahead helps: keep protein intake consistent, maintain activity that preserves strength, and agree a follow-up plan with your team (for example, a slower taper, maintenance strategies, or alternative support). If you stop because goals have been met, expec

Yes — both men and women can use Wegovy when they meet eligibility criteria. Because exposure in pregnancy isn’t recommended, women of child-bearing potential are advised to use effective contraception and to discuss stopping in advance if planning a pregnancy. If you become pregnant, contact your clinical team promptly to review treatment. Apart from pregnancy and breastfeeding considerations, the approach to dosing and monitoring is similar across genders. Equal access in e

In UK services, routine age use focuses on adults within specialist pathways. Use in people under 18 is specialist and not part of standard adult commissioning routes. If a young person is being considered for treatment, this would happen in paediatric services with multidisciplinary input and careful assessment of risks and benefits. Focus on adults in UK guidance In the UK, Wegovy is commissioned primarily for adults who meet strict eligibility criteria. NICE guidance and c

Clinically important interactions are few, but there are practical considerations. Because Wegovy can slow stomach emptying, the...

Suitability depends on your health profile, but many people with common conditions like type 2 diabetes or high blood pressure can use Wegovy within specialist care. If you take insulin or medicines that can cause low blood sugar, your prescriber may adjust doses to reduce hypo risk as appetite changes. Blood-pressure tablets usually continue as normal, with routine monitoring as weight and salt intake shift. People with a history of certain rare endocrine or pancreatic issue

There are no strict dietary restrictions, but simple tweaks help you feel better on treatment. Smaller portions, slower eating, and higher-protein meals reduce nausea and keep you fuller for longer. Early on, many people do better with lighter foods and by limiting very rich, spicy, or greasy dishes. Hydration matters — sip water regularly, and consider a little extra salt if you’ve cut back on processed foods and feel light-headed. Alcohol is best kept moderate, especially w

Energy levels often feel steadier as erratic snacking and large swings in intake settle down. Some people notice early fatigue during dose increases; this usually improves with better hydration, regular meals, and enough protein. If tiredness persists, your team can adjust the titration pace or check for other contributors such as low iron or not eating enough. What to expect in the first weeks Many people describe two parallel experiences at the start. On the one hand, appet

Wegovy was developed by Novo Nordisk as a higher-dose formulation of the GLP-1 receptor agonist semaglutide for chronic weight management, building on earlier experience with semaglutide for type 2 diabetes. Its evidence base comes from large, international STEP trials focused on weight and related health markers, with additional research exploring cardiovascular and kidney outcomes in selected groups. UK adoption is guided by national appraisals and commissioning policies; S

Combination weight loss medications aren’t routine in UK services because evidence for stacking treatments is limited and side-effect...

Wegovy does not “boost metabolism” in the thermogenic sense; its primary action is appetite regulation and reduced intake. As weight decreases, resting energy expenditure typically falls a little — that’s a normal adaptation seen with any weight loss. The meaningful advantage here is reduced hunger and cravings, which makes long-term behaviour change more realistic. Improvements in metabolic risk markers are observed in many users, but they stem from weight reduction and bett